How Ignyta’s “Basket” Clinical Trials Are Different
Ignyta’s clinical trials are designed to pinpoint the patients most likely to benefit from Ignyta’s precision medicines. In order to do that, our trials are structured a little differently. In medical terminology, our trials are referred to as “basket trials.” Basket trials allow us to focus on the specific cause of cancer, regardless of the type or location of cancer. As long as the cancer is caused by the molecular alteration that our drug targets (in the case of entrectinib, we target NTRK, ROS1, and ALK gene fusions), we can enroll patients, whether they have lung cancer, thyroid cancer, or any other type of solid tumor cancer with that alteration.
In this way, Ignyta ensures that we’re opening our trials to the widest possible range of patients, with the largest number of cancer types. It’s yet another way that Ignyta’s precision medicine approach means better accessibility to trials and more options for patients with certain forms of late-stage cancer.
Current Ignyta Cancer Clinical Trials
- STARTRK-2 – Ignyta’s STARTRK-2 clinical trial is actively recruiting NTRK1, NTRK2, NTRK3, ROS1, and ALK positive patients. For more information, visit startrktrials.com.
- RXDX-105-01 – Ignyta’s RXDX-105-01 clinical study targets cancers with RET and BRAF fusions in patients with advanced solid tumors. For more information, visit clinicaltrials.gov.